JPMorgan lowered the firm’s price target on Biogen (BIIB) to $175 from $185 and keeps a Neutral rating on the shares. The analyst updated the company’s model post the Q1 report.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen’s Hold Rating: Balancing New Drug Growth with Declining MS Franchise and Safety Concerns
- Biogen’s International Growth and Promising Pipeline Drive Buy Rating
- Biogen price target lowered to $205 from $255 at Oppenheimer
- Biogen price target lowered to $205 from $217 at RBC Capital
- Biogen price target lowered to $146 from $152 at Morgan Stanley